Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Selective treatment of mixed-lineage leukemia leukemic stem cells through targeting glycogen synthase kinase 3 and the canonical Wnt/β-catenin pathway.

Fung TK, Gandillet A, So CW.

Curr Opin Hematol. 2012 Jul;19(4):280-6. doi: 10.1097/MOH.0b013e3283545615. Review.

PMID:
22525581
2.

Molecular pathways: epigenetic modulation of Wnt-glycogen synthase kinase-3 signaling to target human cancer stem cells.

Benoit YD, Guezguez B, Boyd AL, Bhatia M.

Clin Cancer Res. 2014 Nov 1;20(21):5372-8. doi: 10.1158/1078-0432.CCR-13-2491. Epub 2014 Jul 8. Review.

3.

Menin as a hub controlling mixed lineage leukemia.

Thiel AT, Huang J, Lei M, Hua X.

Bioessays. 2012 Sep;34(9):771-80. doi: 10.1002/bies.201200007. Epub 2012 Jul 24. Review.

4.

GSK3: a multifaceted kinase in Wnt signaling.

Wu D, Pan W.

Trends Biochem Sci. 2010 Mar;35(3):161-8. doi: 10.1016/j.tibs.2009.10.002. Epub 2009 Oct 31. Review.

5.

Glycogen synthase kinase 3: more than a namesake.

Rayasam GV, Tulasi VK, Sodhi R, Davis JA, Ray A.

Br J Pharmacol. 2009 Mar;156(6):885-98. doi: 10.1111/j.1476-5381.2008.00085.x. Epub 2009 Mar 4. Review.

6.

Wnt/beta-catenin signaling in cancer stemness and malignant behavior.

Fodde R, Brabletz T.

Curr Opin Cell Biol. 2007 Apr;19(2):150-8. Epub 2007 Feb 16. Review.

PMID:
17306971
7.

Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.

McCubrey JA, Steelman LS, Bertrand FE, Davis NM, Abrams SL, Montalto G, D'Assoro AB, Libra M, Nicoletti F, Maestro R, Basecke J, Cocco L, Cervello M, Martelli AM.

Leukemia. 2014 Jan;28(1):15-33. doi: 10.1038/leu.2013.184. Epub 2013 Jun 19. Review.

8.

Wnt signaling in adult intestinal stem cells and cancer.

Krausova M, Korinek V.

Cell Signal. 2014 Mar;26(3):570-9. doi: 10.1016/j.cellsig.2013.11.032. Epub 2013 Dec 2. Review.

9.

Re-evaluating the role of Frat in Wnt-signal transduction.

van Amerongen R, Berns A.

Cell Cycle. 2005 Aug;4(8):1065-72. Epub 2005 Aug 1. Review.

PMID:
16082208
10.

Genomic insights into WNT/β-catenin signaling.

Rosenbluh J, Wang X, Hahn WC.

Trends Pharmacol Sci. 2014 Feb;35(2):103-9. doi: 10.1016/j.tips.2013.11.007. Epub 2013 Dec 20. Review.

11.

Targeting Wnt signaling: can we safely eradicate cancer stem cells?

Takahashi-Yanaga F, Kahn M.

Clin Cancer Res. 2010 Jun 15;16(12):3153-62. doi: 10.1158/1078-0432.CCR-09-2943. Epub 2010 Jun 8. Review.

12.

Distinctive microRNA signature associated of neoplasms with the Wnt/β-catenin signaling pathway.

Sun X, He Y, Huang C, Ma TT, Li J.

Cell Signal. 2013 Dec;25(12):2805-11. doi: 10.1016/j.cellsig.2013.09.006. Epub 2013 Sep 13. Review.

PMID:
24041653
13.

β-Catenin in pluripotency: adhering to self-renewal or Wnting to differentiate?

Sineva GS, Pospelov VA.

Int Rev Cell Mol Biol. 2014;312:53-78. doi: 10.1016/B978-0-12-800178-3.00002-6. Review.

PMID:
25262238
14.

Wnt and lithium: a common destiny in the therapy of nervous system pathologies?

Meffre D, Grenier J, Bernard S, Courtin F, Dudev T, Shackleford G, Jafarian-Tehrani M, Massaad C.

Cell Mol Life Sci. 2014 Apr;71(7):1123-48. doi: 10.1007/s00018-013-1378-1. Epub 2013 Jun 9. Review.

PMID:
23749084
15.

Regulation of tumorigenic Wnt signaling by cyclooxygenase-2, 5-lipoxygenase and their pharmacological inhibitors: A basis for novel drugs targeting cancer cells?

Roos J, Grösch S, Werz O, Schröder P, Ziegler S, Fulda S, Paulus P, Urbschat A, Kühn B, Maucher I, Fettel J, Vorup-Jensen T, Piesche M, Matrone C, Steinhilber D, Parnham MJ, Maier TJ.

Pharmacol Ther. 2016 Jan;157:43-64. doi: 10.1016/j.pharmthera.2015.11.001. Epub 2015 Nov 6. Review.

PMID:
26549540
16.

Targeting the leukemic stem cell: the Holy Grail of leukemia therapy.

Misaghian N, Ligresti G, Steelman LS, Bertrand FE, Bäsecke J, Libra M, Nicoletti F, Stivala F, Milella M, Tafuri A, Cervello M, Martelli AM, McCubrey JA.

Leukemia. 2009 Jan;23(1):25-42. doi: 10.1038/leu.2008.246. Epub 2008 Sep 18. Review.

17.

Targeting leukemia stem cells: which pathways drive self-renewal activity in T-cell acute lymphoblastic leukemia?

Belmonte M, Hoofd C, Weng AP, Giambra V.

Curr Oncol. 2016 Feb;23(1):34-41. doi: 10.3747/co.23.2806. Epub 2016 Feb 18. Review.

18.

Therapeutic targeting of acute myeloid leukemia stem cells.

Pollyea DA, Jordan CT.

Blood. 2017 Mar 23;129(12):1627-1635. doi: 10.1182/blood-2016-10-696039. Epub 2017 Feb 3. Review.

PMID:
28159738
19.

Inhibitors of the Menin-Mixed Lineage Leukemia (MLL) Interaction.

Manka J, Daniels RN, Dawson E, Daniels JS, Southall N, Jadhav A, Zheng W, Austin C, Grembecka J, Cierpicki T, Lindsley CW, Stauffer SR.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2011 Mar 31 [updated 2013 Feb 28].

20.

Aberrant Wnt Signaling in Leukemia.

Staal FJ, Famili F, Garcia Perez L, Pike-Overzet K.

Cancers (Basel). 2016 Aug 26;8(9). pii: E78. doi: 10.3390/cancers8090078. Review.

Supplemental Content

Support Center